Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
84 patients around the world
Available in Mexico, United States
Participants who complete the Week 96 visit will be eligible to enroll in an Extension
Study in which they may continue to receive DOR until it is commercially available, or
for up to an additional 224 weeks (whichever comes first).